GLP-1s and Mental Health: What 10 Studies Actually Found (2026)

10 papers · each one re-checked on PubMed · last verified October 2026

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

In 2023 a European regulator flagged a possible link between these drugs and suicidal thoughts, and the research world moved fast. What emerged has mostly pointed the other way, but the evidence is lopsided, and the imbalance is worth understanding before reading any of it. The FDA reached the same conclusion on its own data: in January 2026, after a review that found no increased risk, it asked for the suicidal-behavior warning to be removed from the Wegovy, Zepbound and Saxenda labels. Two randomized trials and one meta-analysis of randomized trials appear below; everything else is observational. Cohort studies and adverse-event databases are excellent at raising a question and structurally incapable of settling one, because people given a drug are unlike people not given it, in ways no statistical adjustment fully removes. Where the randomized and observational evidence disagree here, the randomized evidence should win. Where they agree, as they increasingly do on substance use, the case gets interesting.

Ranked papers

#1

Association of semaglutide with risk of suicidal ideation in a real-world cohort

Wang W, Volkow ND, Berger NA, et al. · Nat Med · 2024

What it measured: New and recurring suicidal thoughts, against other diabetes and weight drugs

A cohort of 240,618 patients drawn from a large electronic-records network, compared against matched patients on other diabetes and weight drugs. New suicidal ideation was substantially lower on semaglutide in both the obesity and diabetes groups. It is observational, so it cannot establish cause. The design choice that makes it worth reading is the comparison against another drug rather than against nobody, which removes much of the difference between people who seek treatment and people who do not.

PMID 38182782 ↗DOI 10.1038/s41591-023-02672-2 ↗

#2

GLP-1 Receptor Agonist Use and Risk of Suicide Death

Ueda P, Söderling J, Wintzell V, et al. · JAMA Intern Med · 2024

What it measured: Suicide deaths and self-harm, against SGLT2 inhibitor users, in two national registries

The strongest observational evidence here, because of its design rather than its size. Sweden's and Denmark's national registers followed 124,517 people starting a GLP-1 against 174,036 starting an SGLT2 inhibitor, a comparator chosen because it treats the same patients. Over a mean 2.5 years, suicide deaths were 0.23 against 0.18 per 1,000 person-years, a difference that did not reach significance. Suicide deaths and nonfatal self-harm counted together were less frequent on GLP-1s (hazard ratio 0.83), and new depression and anxiety diagnoses did not differ. National registers capture everyone, which removes the reporting bias that cripples the database studies below.

PMID 39226030 ↗DOI 10.1001/jamainternmed.2024.4369 ↗

#3STEP 1/2/3/5 post-hoc

Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials

Wadden TA, Brown GK, Egebjerg C, et al. · JAMA Intern Med · 2024

What it measured: Suicidal thoughts and depression scores, measured prospectively on validated scales

The best randomized psychiatric-safety data available at the obesity dose: STEP 1, 2 and 3 pooled (3,377 participants), with STEP 5's 304 analyzed separately, and suicidality measured prospectively on a validated scale rather than reconstructed afterwards. On the drug and on placebo alike, 1% or fewer reported suicidal thoughts or behavior, with no difference between groups, and depression scores improved slightly more on the drug. One limitation shapes everything. These trials excluded people with serious existing mental illness, so this says little about the population most at risk.

PMID 39226070 ↗DOI 10.1001/jamainternmed.2024.4346 ↗

#4

Suicide and Self-Harm Events With GLP-1 Receptor Agonists in Adults With Diabetes or Obesity: A Systematic Review and Meta-Analysis

Ebrahimi P, Batlle JC, Ayati A, et al. · JAMA Psychiatry · 2025

What it measured: Suicide, self-harm, suicidal thoughts and depression, pooled across randomized trials

The largest randomized-only synthesis: 27 placebo-controlled trials in diabetes or obesity, with 59,396 participants (32,354 on a GLP-1 drug). Suicide- and self-harm-related events were very rare in both groups (0.047 against 0.042 per 100 person-years; rate ratio 0.76, not significant), and the result did not change by diabetes status or by drug. The caveat is statistical rather than clinical. None of these trials was powered to detect rare psychiatric events, so pooling underpowered trials produces a wide confidence interval rather than a clean absence.

PMID 40105856 ↗DOI 10.1001/jamapsychiatry.2025.0091 ↗

#5

The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)

McIntyre RS, Mansur RB, Rosenblat JD, et al. · Expert Opin Drug Saf · 2024

What it measured: Whether suicidality was reported disproportionately often in the FDA's adverse-event database

The pharmacovigilance analysis that documented the formal signal, using the FDA's spontaneous-reporting system after the 2023 European alert. Suicidal ideation was reported disproportionately often with semaglutide and liraglutide, but suicidal behavior, suicide attempts and completed suicide were not, for any drug in the class. What this design cannot do is tell you the rate of anything. Nobody knows how many people took the drug without reporting an event, and a drug in the news generates reports for that reason alone. It records that a signal existed, not that a risk does.

PMID 38087976 ↗DOI 10.1080/14740338.2023.2295397 ↗

#6

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase)

McIntyre RS, Mansur RB, Rosenblat JD, et al. · J Affect Disord · 2025

What it measured: Whether suicidality was reported disproportionately often in the WHO's global database

The same team repeating the analysis in the World Health Organization's global database, and the result was mixed. Suicidal ideation was again reported disproportionately often with semaglutide and liraglutide, and with tirzepatide too, but suicide attempts and completed suicides were reported significantly less often than expected for several drugs in the class. It shares every limitation of the design: no denominator, no timing, and heavy confounding by why people were prescribed the drug in the first place.

PMID 39433133 ↗DOI 10.1016/j.jad.2024.10.062 ↗

#7Semaglutide AUD RCT

Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial

Hendershot CS, Bremmer MP, Paladino MB, et al. · JAMA Psychiatry · 2025

What it measured: How much people drank in a monitored session, plus craving and drinks per drinking day

The first randomized test of any drug in this class against alcohol use disorder: 48 adults, none of them seeking treatment, on low-dose semaglutide or placebo for nine weeks. It reduced how much people drank in a laboratory setting, how much they drank on the days they drank, and how much they craved it, and cut cigarettes among smokers. It did not move how many days people drank, or drinks per calendar day. The trial was small and short, but it matters as proof that the cohort signals reflect real pharmacology.

PMID 39937469 ↗DOI 10.1001/jamapsychiatry.2024.4789 ↗

#8

Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes: Target Trial Emulation Using Real-World Data

Wang W, Volkow ND, Berger NA, et al. · Ann Intern Med · 2024

What it measured: New tobacco-use-disorder diagnoses, and quit-smoking prescriptions and visits

A target-trial emulation among people with both type 2 diabetes and a tobacco use disorder: 222,942 new users of diabetes drugs, 5,967 of them on semaglutide, compared against seven other drug classes. Starting semaglutide was associated with fewer tobacco-related medical encounters and fewer smoking-cessation prescriptions and counseling visits, against every comparator including other GLP-1 drugs, with most of the difference appearing within 30 days. Consistency across comparators is a real strength. The unfixable problem is that wanting to quit is unmeasured, and people who pursue a weight drug may differ on exactly that.

PMID 39074369 ↗DOI 10.7326/M23-2718 ↗

#9

Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study

Wang W, Volkow ND, Berger NA, et al. · Mol Psychiatry · 2024

What it measured: New and repeat cannabis-use-disorder diagnoses, against other diabetes drugs

The same approach applied to cannabis use disorder, across cohorts of 85,223 with obesity and 596,045 with type 2 diabetes. New diagnoses were roughly 44% and 60% lower on semaglutide, with recurrence down too. It fits the pattern the alcohol, tobacco and opioid work shows, which is what makes a shared reward-pathway mechanism plausible. Cannabis use is poorly captured in medical records, so what is being measured is diagnosis rather than use.

PMID 38486046 ↗DOI 10.1038/s41380-024-02498-5 ↗

#10

Semaglutide and Opioid Overdose Risk in Patients With Type 2 Diabetes and Opioid Use Disorder

Wang W, Volkow ND, Wang Q, et al. · JAMA Netw Open · 2024

What it measured: Opioid overdoses among patients who already had opioid use disorder

The substance-use series taken to its most serious endpoint: 33,006 patients with diabetes and existing opioid use disorder, 3,034 of them on semaglutide, where twelve-month overdose risk ran 42 to 68% lower on semaglutide depending on the comparator, including other GLP-1 drugs. People who stay engaged with medical care both take their prescriptions and overdose less often, and no adjustment fully separates those. No randomized trial in opioid use disorder has reported.

PMID 39320894 ↗DOI 10.1001/jamanetworkopen.2024.35247 ↗

About this list

Obesity medicine throws up the same handful of questions over and over, and we answer them with ranked lists anchored to the papers themselves. On 2026-10-30 every citation below was put back through PubMed. Where a trial has a registry entry, the card carries that link too, alongside the PubMed one.

Browse our full index of research lists or our long-form research articles.